Treatment of resistant Hodgkin's disease with CCNU, etoposide and prednimustine (CEP).
Starting in January 1984, 63 patients with resistant Hodgkin's disease received CEP as salvage-usually third-line-chemotherapy. Complete response (CR) was achieved in 3%, partial response (PR) in 51%. The median duration of remission (CR + PR) was greater than 15 months. Treatment was generally well tolerated. Our results confirm that CEP is an effective therapeutic regimen in resistant Hodgkin's disease.
Szántó
I
I
Department of Hematology, National Institute of Oncology, Budapest, Hungary.
Fleischmann
T
T
Eckhardt
S
S
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008875:Middle Aged; D011238:Prednimustine / Q000008:administration & dosage
D005047:Etoposide; D008130:Lomustine; D011238:Prednimustine